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Abstract
AIM: To investigate variants of immunity-related GT-
Pase family M (IRGM) and NKX2-3 genes and genotype-
phenotype in Eastern European patients with inflamma-
tory bowel disease (IBD). 
METHODS: We analyzed 1707 Hungarian and Czech 
subjects with Crohn’s disease (CD) (n  = 810, age: 37.1 
± 12.6 years, duration: 10.7 ± 8.4 years) and ulcer-
ative colitis (UC) (n  = 428, age: 43.7 ± 15.0 years, 
duration: 12.6 ± 9.9 years), as well as 469 healthy 
controls. IRGM rs13361189, NKX2-3 rs10883365 and 
ECM1 rs13294 polymorphisms were tested by LightCy-
cler allele discrimination. Detailed clinical phenotypes 
were determined by reviewing the medical charts.
RESULTS: NKX2-3 rs10883365 variant allele was as-
sociated with increased risk for CD (P  = 0.009, OR = 
1.24, 95% CI = 1.06-1.48) and UC (P  = 0.001, OR = 
1.36, 95% CI = 1.13-1.63), whereas variant IRGM allele 
increased risk for CD (P  = 0.029, OR = 1.36, 95% CI = 
1.03-1.79). In contrast, ECM1 rs13294 was not associat-
ed with either CD or UC. In CD, the variant IRGM allele 
was associated with a colon-only location (P  = 0.02, OR 
= 1.62, 95% CI = 1.07-2.44), whereas in UC, the ECM1 
variant was associated with cutaneous manifestations 
(P  = 0.002, OR = 3.36, 95% CI = 1.48-7.63). Variant 
alleles did not predict resistance to steroids or azathio-
prine, efficacy of infliximab, or need for surgery.
CONCLUSION: NKX2-3 and IRGM are susceptibility loci 
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for IBD in Eastern European patients. Further studies 
are needed to confirm the reported phenotype-genotype 
associations.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel diseases (IBDs) are multifactorial with 
both environmental and genetic components; the latter 
displaying heterogeneity in terms of  disease presentation 
as well as response to treatment[1]. Crohn’s disease (CD) 
has a strong genetic component, and to date, at least nine 
susceptibility loci have been identified[2]. The first, and most 
consistently replicated critical mutations have been found 
in the NOD2/CARD15 gene on chromosome 16 (IBD1). 
Other loci encode genes that are involved in a number of  
homeostatic mechanisms: innate pattern recognition recep-
tors (including NOD2/CARD15, TLR4 and CARD9), dif-
ferentiation of  Th17-lymphocytes (IL-23R, JAK2, STAT3, 
CCR6 and ICOSLG), autophagy [ATG16L1, immunity-re-
lated GTPase family M (IRGM) and LRRK2], maintenance 
of  epithelial barrier integrity (IBD5, DLG5, PTGER4, 
ITLN1, DMBT1 and XBP1), and orchestration of  the sec-
ondary immune response (HLA-region, TNFSF15/TL1A, 
IRF5, PTPN2, PTPN22, NKX2-3, IL-12B, IL-18RAP and 
MST1)[3-6]. As the incidence of  IBD is rapidly increasing in 
some parts of  Eastern Europe[1], it is of  great importance 
to study social and environmental, as well as host-genetic 
factors that might underlie this trend. 
The IRGM gene is located on chromosome 5q33.1, 
and encodes an autophagy-inducing protein and belongs 
to the immunity-related guanosine triphosphatases (IRGs), 
also known as p47 guanosine triphosphatases. IRGs play 
an important role in host defense against intracellular 
pathogens[7]. Genetic association of  the autophagy genes, 
autophagy-related 16-like 1 (ATG16L1) and IRGM has 
been suggested in adult-onset CD by genome-wide as-
sociation scan studies (GWASs), but not in UC[5,6,8-10]. 
Although a meta-analysis of  the three index GWASs 
has implicated a single nucleotide polymorphism (SNP; 
rs11747270) based on imputed data with an OR of  1.33[10], 
other studies including a new meta-analysis[11] have con-
firmed the IRGM signal on rs13361189 and rs4958847 
immediately flanking IRGM. 
Recently, the rs13361189 variant, upstream of  IRGM, 
has been shown to be in perfect linkage disequilibrium 
with a 20-kb deletion polymorphism that affects the ex-
pression of  IRGM (and cellular autophagy) in a tissue-
specific manner[9]. These results suggest that the CD asso-
ciation at IRGM arises from an alteration in IRGM regula-
tion that affects the efficacy of  autophagy, and identifies 
rs13361189 and its strongly correlated neighbors at the 5’ 
end of  IRGM, including the 20-kb deletion polymorphism 
as a likely causal variant.
Association between the rs10883365 variant of  NK2 
transcription factor related, locus 3 (NKX2-3) gene on 
chromosome 10q24.2 and susceptibility of  CD has been 
reported in Western Europe, including The Wellcome 
Trust Case Control Consortium (WTCCC) GWA and a 
replication study from The Netherlands, and in Japan, 
with an OR of  1.2-1.6[12-14]. In addition, a modest associa-
tion (P = 3.3 × 10-4 in the ulcerative colitis panel and P = 
2.4 × 10-6 using the expanded WTCCC control panel) has 
also been reported between rs10883365 and UC in a non-
synonymous SNP scan by Fisher et al[15]. NKX2-3-deficient 
mice show severe defects in gut development; primarily 
in the epithelium of  the small intestine[16]. In addition, the 
lymphoid organs of  these mice, including the spleen and 
Peyer’s patches, have abnormal tissue architecture and ab-
normalities in the migration and segregation of  B and T 
cells[17], however, the exact mechanism is unknown. 
ECM1, on chromosome 1q21.2, is also a plausible can-
didate gene for UC; it encodes extracellular matrix protein 
1, a glycoprotein expressed in small and large intestine, 
and it interacts with the basement membrane and inhibits 
matrix metalloproteinase[18]. Notably, ECM1 strongly acti-
vates nuclear factor-κB signaling, a key immune regulator. 
Expression is upregulated in colorectal cancer and metas-
tases, which implicates ECM1 in epithelial-stromal interac-
tion[18]. Of  note, the WTCCC observed modest association 
between these ECM1 SNPs and ankylosing spondylitis, 
a related inflammatory disorder (P = 0.0041 and 0.0044), 
respectively[13]. More recently, an association between the 
rs3737240 and rs13294 variants of  ECM1 and UC suscep-
tibility was reported in a GWAS by Fisher et al[15], with an 
OR of  1.3-1.4 for the homozygous carriage of  the variant 
allele. rs3737240 and rs13294 encode substitutions T130M 
and G290S: Thr130, residing within a collagen Ⅳ binding 
domain, is conserved in primates, whereas Gly290 is not. 
Finally, data about the pharmacogenetics of  IBD are 
still limited. Resistance to steroids is associated with high 
expression of  β-glucocorticoid receptors (hGRβ) and over-
expression of  MDR1 has been found in patients who fail 
steroid therapy and require surgery[19]. In contrast, accord-
ing to our group’s earlier results, the presence of  the DLG5 
Arg30Gln variant allele, but not variants in ABCG2 or 
MDR1 genes, predicted resistance to steroids[20,21]. Vermeire 
et al[22] have reported a lack of  association between the 
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presence of  NOD2 mutations and response to infliximab 
therapy, and later, the same group reported an association 
between the presence of  Fas ligand -843C/T variant and 
response to infliximab[23]. 
In light of  the lack of  data in Eastern European coun-
tries, our aim was to investigate the prevalence of  IRGM 
rs13361189, NKX2-3 rs10883365 and ECM1 rs13294 
variants in large independent cohorts of  Czech and Hun-
garian IBD patients. We also aimed to investigate a pos-
sible association between genotype and clinical phenotype, 
need for surgery, and response to medical therapy. 
MATERIALS AND METHODS
Study population
One thousand seven hundred and seven unrelated IBD 
patients (CD: n = 810, age: 37.1 ± 12.6 years, duration: 
10.7 ± 8.4 years and UC: n = 428, age: 43.7 ± 15.0 years, 
duration: 12.6 ± 9.9 years) and 469 healthy subjects (blood 
donors) from Hungary and the Czech Republic were in-
vestigated. The clinical data of  the CD and UC patients 
are presented in Table 1. A detailed clinical phenotype was 
available in 789 CD and 422 UC patients.
The diagnosis was based on the Lennard-Jones crite-
ria[24]. Age; age at onset; presence of  extraintestinal mani-
festations [arthritis: peripheral and axial; ocular manifesta-
tions: conjunctivitis, uveitis and iridocyclitis; skin lesions: 
erythema nodosum and pyoderma gangrenosum; and he-
patic manifestations: primary sclerosing cholangitis (PSC)]; 
frequency of  flare-ups (frequent relapses: > 1 clinical 
relapse/year); therapeutic effectiveness (e.g. steroid and/
or immunosuppressive use, steroid resistance); need for 
surgery (resections); the presence of  familial IBD; smok-
ing habits; and in CD, perianal involvement, were investi-
gated by reviewing the medical charts by the physician and 
completing a questionnaire. The disease phenotype (age 
at onset, duration, location and behavior) was determined 
according to the Montreal classification[25].
The control group for mutation analysis consisted of  
469 age- and sex-matched healthy blood donors (male/
female: 251/218, age: 40.5 ± 11.5 years old). Control sub-
jects did not have any gastrointestinal and/or liver diseases 
and were selected from consecutive blood donors in Bu-
dapest, Veszprem, Debrecen and Prague. The study pro-
tocol was approved by the Ethical and Science Committee 
of  the Ministry of  Health. Each patient was informed of  
the nature of  the study and gave signed informed consent.
Genotyping and DNA isolation
Genomic DNA was isolated from whole blood according 
to the manufacturers’ description with High Pure PCR 
Template preparation Kit (Roche, Budaors, Hungary).
Detection of IRGM (rs13361189,g.11386323T>C), ECM1 
(rs13294, c.1243A>G, p.Ser415Gly, g.975342G>A) and 
NKX2-3 (rs1083365, g.20036290G>A) polymorphisms
Genotyping was performed using the LightCycler (Roche 
Diagnostics, Basel, Switzerland) allelic discrimination 
system. Amplification primers and hybridization probes 
were designed by the LightCycler Probe Design software 
(Roche Diagnostics). All oligonucleotides were synthe-
sized by VBC Biotech (Vienna, Austria). The following 
amplification primers and hybridization probes were used 
for genotyping IRGM: IRGM-LCF: 5'-ATGGACAGT-
CAGTACCCTGCAC-3', IRGM-LCR: 5'-CTCTTTAC-
CATTGTACTCCTTGTGCC-3', IRGM-ANC: 5'-LC Red 
640-TGCTCAGCGGGTACAGTTTAGAAAGGGAA-
Phosphate-3', IRGM-SENS: 5'-GAAAATCGGATG-
TATATTAGTAGACCC-Fluorescein-3'. 
The amplification primers and hybridization probes 
used for genotyping of  ECM1 were: ECM1-LCF: 5'- 
ACCCACCACCACTTGTGT-3', ECM1-LCR: 5'-TGCTT-
GGTGAGAACTCTTTGGTTT-3', ECM1-ANC: 5'-LC 
Red 640-TCAAGATGTCCCGGTCATAGTTGGGG-
TAAGGAG-Phosphate-3', ECM1-SENS: 5'-TGACTC-
GACCGATGTCAAT-Fluorescein-3'. 
The amplification primers and hybridization probes 
used for genotyping of  NKX2-3 were: NKX2-LCF: 
Table 1  Clinical characteristics of patients with inflammatory 
bowel diseases
CD
 (n  = 810)
UC
 (n  = 428)
Male/female (n) 434/376 202/226
Age (yr)   37.1 ± 12.6   43.7 ± 15.0
Age at presentation (yr)1   26.5 ± 10.6   31.3 ± 13.4
Duration (yr)1 10.7 ± 8.4 12.6 ± 9.9
Familial IBD1 11.8%   7.6%
Location in CD1
   L1 28.2%
   L2 18.9% -
   L3 51.2%
   L4 only   1.7%
   All L4   7.9%
Maximum extent in UC1 
   Proctitis -   7.8%
   Left-sided 52.3%
   Extensive 39.9%
Behavior in CD1
   B1 34.9%
   B2 34.5% -
   B3 30.7%
Perianal disease1 41.2% -
Frequent relapse in CD/chronic 
continuous in UC1
39.9% 27.6%
Arthritis1 38.6% 27.1%
Cutaneous1   7.8%   5.9%
Occular1   7.7%   3.8%
PSC1   2.4%   3.8%
Steroid use/refractory1 81.1%/11.6% 66.2%/12.3%
Azathioprine use1 68.3% 29.3%
Anti-TNF use1 33.2% 10.4%
Surgery in CD/colectomy in UC1 50.9% 10.0%
Smoking habits2 
   No 55.1% 71.6%
   Yes 31.3% 12.4%
   Previous 13.6% 16.0%
1Clinical phenotype available in 789 Crohn's disease (CD) and 422 ulcer-
ative colitis (UC) patients; 2Available in 691 CD and 388 UC patients. L1: 
Ileal; L2: Colon; L3: Ileocolonic; L4: Upper gastrointestinal; B1: Inflam-
matory; B2: Stenosing; B3: Penetrating. IBD: Inflammatory bowel disease; 
TNF: Tumor necrosis factor.
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5'-CCGCATAAGACGTTACTTAAACATGT-3' , 
NKX2-LCR: 5'-GCTATCTACTCGAAACTGTCT-
GC-3', NKX2-ANC-2: 5'-TCTCCCCGGGGGTCAC-
GTTG-Fluorescein-3', NKX2-SENS-2: 5'-LC Red 610- 
ACAAACACCTTCAAACCGTC-Phosphate-3'.
Polymerase chain reaction (PCR) was performed by 
LightCycler 480 real-time PCR System (Roche), in a reac-
tion volume of  20 μL with 50 ng genomic DNA, 10 μL 
2 × PCR Master Mix (Promega), and 5 pmol of  the re-
spective labeled oligonucleotides (sensor and anchor). 
For IRGM and NKX2-3, an asymmetric multiplex sys-
tem was used for simultaneous amplification of  the two 
fragments with 3:10 pmol forward:reverse (F:R) amplifi-
cation oligonucleotides and 10:3 F:R amounts for IRGM 
and NKX2-3 SNPs, respectively. Similarly, for ECM1, 
an asymmetric PCR was applied with a 10:3 pmol F:R 
primer mix for amplification in a separate reaction. Cy-
cling conditions were as follows: initial denaturation at 
95℃ for 3 min, followed by 35 cycles of  denaturation at 
95℃ for 20 s, annealing at 55℃ for 30 s, and extension 
at 72℃ for 45 s, with a ramping rate of  4.4℃/s.
After amplification, a melting curve analysis was per-
formed by cooling the samples to 40℃, followed by gradual 
heating to 80℃ with a ramp rate of  0.04℃/s. The decline 
in fluorescence was continuously monitored. Melting curves 
were converted to melting peaks with wild-type and vari-
ant alleles showing distinct melting points. For the IRGM 
and NKX2-3 multiplex PCR, color compensation was 
performed to compensate for the fluorescence crosstalk 
between detection channels. Genotype calling was carried 
out by two independent investigators.
Statistical methods 
Variables were tested for normality using Shapiro Wilk’s 
W test. A t test with separate variance estimates, χ2 test and 
χ2 test with Yates correction were used to evaluate differ-
ences between IBD patients and controls, as well as within 
subgroups of  IBD patients. Logistic regression was used to 
compare genetic and clinical data and results are expressed 
as OR with 95% CI. P < 0.05 was considered as significant. 
For the statistical analysis, SPSS version 15.0 (SPSS Inc., 
Chicago, IL, USA) was used. Statistical analysis was per-
formed by Lakatos PL with the assistance of  a statistician.
RESULTS
Association between NKX2-3, IRGM and ECM1 and 
disease susceptibility
All investigated polymorphisms were in Hardy-Weinberg 
equilibrium (P = 0.38-0.95). The success rate of  the ge-
notyping assays was 98%-99%. The genotype and allele 
frequencies are presented in Table 2. NKX2-3 rs10883365 
variant allele was associated with increased risk for CD (P 
= 0.018 after Bonferroni correction, OR = 1.24, 95% CI 
= 1.06-1.48) and UC (P = 0.003 after Bonferroni correc-
tion, OR = 1.36, 95% CI = 1.13-1.63), whereas the variant 
IRGM allele increased the risk of  CD (P = 0.04 after Bon-
ferroni correction, OR = 1.36, 95% CI = 1.03-1.79). The 
association between NKX2-3 rs10883365 variant and IBD 
was also significant in the genotypic and dominant models. 
A similar trend was noted between IRGM and CD. In con-
trast, ECM1 rs13294 was not associated with either CD or 
UC. The combination of  IRGM carrier/NKX2-3 homo-
zygote genotype was significantly higher in CD compared 
to the controls (7.2% vs 2.1%, P < 0.0001 after Bonferroni 
correction, OR = 3.55, 95% CI = 1.80-7.01). 
Role of NKX2-3, IRGM and ECM1 variants in predicting 
sex, familial disease, age at onset, disease location, 
phenotype or extraintestinal manifestations
In CD, presence of  the variant IRGM allele was associat-
ed with colon-only location (in carriers: 25% vs wild-type: 
17.1%, P = 0.04 after Bonferroni correction, OR = 1.62, 
95% CI = 1.07-2.44, Figure 1A). In UC, homozygous car-
riage of  the ECM1 variant allele was associated with cuta-
neous manifestations (11.5% in homozygotes vs 3.7% in 
patients with other genotypes, P = 0.004 after Bonferroni 
correction, OR = 3.36, 95% CI = 1.48-7.63, Figure 1B). 
No other significant associations were found in either CD 
or UC patients (data not shown).
Association between NKX2-3, IRGM and ECM1 and 
response to medical therapy or need for surgery 
We also investigated the association between the NKX2-3, 
IRGM and ECM1 variants and the response to steroids, 
25
20
15
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5
0
%
    Carrier                Wild-type
A
12
10
8
6
4
2
0
%
          Homozygous carrier               Wild-type
B
Figure 1  Association between immunity-related GTPase family, M and 
ECM1 and disease phenotype in patients with inflammatory bowel diseases. 
A: Association between the IRGM rs13361189 variant and disease location in 
Crohn’s disease. P = 0.04, OR = 1.62, 95% CI: 1.07-2.44; B: Association be-
tween homozygous carriage of the ECM1 rs13294 variant allele and cutaneous 
manifestations in ulcerative colitis. P = 0.004, OR = 3.36, 95% CI: 1.48-7.63.
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infliximab or azathioprine or the need for surgery in pa-
tients with CD. Two hundred and sixty-three unrelated 
CD patients were treated with anti-tumor necrosis factor 
(TNF): 259 received infliximab and four, adalimumab, two 
of  whom were treated after secondary loss of  response to 
infliximab therapy. Overall, there was no association be-
tween the presence of  the above variants and short-term 
response (assessed at week 12) to infliximab induction 
therapy [5 mg/kg at weeks 0, 2 and 6; partial response: 
Crohn’s disease activity index (CDAI) decreased by ≥ 70 
points and/or ≥ 50% decrease in the number of  draining 
fistulas; remission: CDAI < 150 or closure of  all fistulas]; 
steroid use/resistance; azathioprine use; or need for sur-
gery (data not shown). Similarly, no association was found 
between either of  the variants and steroid use/resistance, 
azathioprine use or need for surgery in patients with UC 
(data not shown). 
DISCUSSION
This is the first report on the prevalence of  the IRGM 
rs13361189, NKX2-3 rs10883365 and ECM1 rs13294 vari-
ants, in large, independent IBD cohorts from Eastern Eu-
rope. The variant NKX2-3 allele conferred a risk in both 
UC and CD, whereas the IRGM rs13361189 variant allele 
was associated with increased risk for CD. In addition, the 
IRGM variant was associated with disease location in CD. 
The genotype and allele frequencies for IRGM and 
NKX2-3 variants in CD, UC and controls reported in 
the present study were in line with most previous re-
ports in Caucasian populations, whereas the frequency 
of  the variant ECM1 rs13294 allele was approximately 
10% higher in both IBD and controls, compared to that 
reported in previous studies[7,8,12,13,15,26].
We confirmed that the IRGM rs13361189 variant 
was associated with disease susceptibility in CD in East-
ern European populations. The allelic OR of  1.36 (95% 
CI = 1.03-1.79) was in the range reported in Caucasian 
populations (OR = 1.38-1.56)[7,13] and in a recent meta-
analysis (OR = 1.34)[10]. Similar genotype distributions 
were observed in both the Czech and Hungarian cohort, 
however, due to the low variant allele frequency, the dif-
ference became significant only in the combined analysis. 
A similar tendency (P = 0.06) was observed in the ge-
notypic and dominant model. In contrast, in the present 
study we failed to replicate the weak association between 
IRGM and UC (rs13361189 P = 0.0069, pooled OR = 
1.16; rs4958847 P = 0.014, pooled OR = 1.13) that was 
reported recently in a Spanish meta-analysis[10]. Of  note, 
the present study was underpowered to detect such small 
Table 2  Association between NKX2-3, IRGM and ECM1 polymorphisms and disease susceptibility in patients with inflammatory 
bowel disease
WT (%) HET (%) HOM (%) P  value Carrier (%) P  value OR (95%CI) MAF P  value OR (95%CI)
IRGM rs13361189
All CD (n = 808) 636 (78.7) 156 (19.3) 16 (2.0) 0.0601 172 (21.3) 0.0601 - 188 (11.6) 0.029 1.36 (1.03-1.79) 
Hungarian CD (n = 456) 355 (77.9)   89 (19.5) 12 (2.6) NS1,2 101 (22.1) NS1,2 - 113 (12.4) NS1,2 -
Czech CD (n = 352) 281 (79.8)   67 (19.0)   4 (1.2) NS1,2   71 (20.2) NS1,2 -   75 (10.7) NS1,2 -
All UC (n = 428) 351 (82.0)   76 (17.8)   1 (0.2) NS1,2   77 (18.0) NS1,2 - 78 (9.1) NS1,2 -
Hungarian UC (n = 274) 221 (80.7)   52 (19.0)   1 (0.3) NS1,2   53 (19.3) NS1,2 - 54 (9.9) NS1,2 -
Czech UC (n = 154) 130 (84.4)   24 (15.6) 0 NS1,2   24 (15.6) NS1,2 - 24 (7.8) NS1,2 -
All controls (n = 460) 382 (83.0)   75 (16.3)   3 (0.7) -   78 (17.0) - - 81 (8.8) - -
Hungarian controls (n = 265) 217 (81.9)   46 (17.4)   2 (0.7) -   48 (18.1) - - 50 (9.4) - -
Czech controls (n = 195) 165 (84.6)   29 (14.9)   1 (0.5) -   30 (15.4) - - 31 (7.9) - -
NKX2 rs 10883365
All CD (n = 810) 208 (25.7) 389 (48.1) 213 (26.2) 0.0101 602 (74.3) NS1,2 - 815 (50.3) 0.009 1.24 (1.06-1.48)
Hungarian CD (n = 457) 115 (25.2) 220 (48.1) 122 (26.7) NS1,2 342 (74.8) NS1,2 - 464 (50.8) NS1,2 -
Czech CD (n = 353)   93 (26.3) 169 (47.9)   91 (25.8) 0.0701 260 (73.7) NS1 - 351 (49.7)  0.0301 1.31 (1.03-1.68)
All UC (n = 427)   90 (21.1) 226 (52.9) 111 (26.0) 0.0041 337 (78.9) 0.0061 1.52 (1.13-2.08) 448 (52.5) 0.001 1.36 (1.13-1.63)
Hungarian UC (n = 274)   56 (20.4) 152 (55.5)   66 (24.1) NS1,2 218 (79.6) 0.0701 284 (51.8) 0.060
Czech UC (n = 153)   34 (22.2)   74 (48.4)   45 (29.4) 0.0171 119 (77.8) 0.0461 1.63 (1.01-2.65) 164 (53.6)  0.0051 1.53 (1.14-2.07)
All controls (n = 469) 136 (29.0) 245 (52.2)   88 (18.8) - 333 (71.0) - - 421 (44.9) - -
Hungarian controls (n = 271)   73 (26.9) 145 (53.5)   53 (19.6) - 198 (73.1) - - 251 (46.3) - -
Czech controls (n = 198)   63 (31.8) 100 (50.5)   35 (17.7) - 135 (68.2) - - 170 (42.9) - -
ECM1 rs13294
All CD (n = 807) 139 (17.2) 392 (48.6) 276 (34.2) NS1,2 688 (82.8) NS1,2 - 944 (58.5) NS1,2 -
Hungarian CD (n = 455)   89 (19.6) 228 (50.1) 138 (30.3) NS1,2 366 (80.4) NS1,2 - 504 (55.4) NS1,2 -
Czech CD (n = 352)   50 (14.2) 164 (46.6) 138 (39.2) NS1,2 302 (85.8) NS1,2 - 440 (62.5) NS1,2 -
All UC (n = 428)   77 (18.0) 225 (52.6) 126 (29.4) NS1,2 351 (82.0) NS1,2 - 477 (55.7) NS1,2 -
Hungarian UC (n = 275)   44 (16.0) 156 (56.1)   75 (27.3) NS1,2 231 (84.0) NS1,2 - 306 (55.6) NS1,2 -
Czech UC (n = 153)   33 (21.6)   69 (45.1)   51 (33.3) NS1,2 120 (78.4) NS1,2 - 171 (55.9) NS1,2 -
All controls (n = 463)   90 (19.4) 222 (47.9) 151 (32.6) - 373 (80.6) - - 524 (56.6) - -
Hungarian controls (n = 265)   56 (21.1) 124 (46.8)   85 (32.1) - 209 (78.9) - - 294 (55.5) - -
Czech controls (n = 198)   34 (17.2)   98 (49.5)   66 (33.3) - 164 (82.8) - - 230 (58.1) - -
1P value vs controls; 2P value Crohn's disease (CD) vs ulcerative colitis (UC). WT: Wild-type; HET: Heterozygous carrier; HOM: Homozygous carrier; MAF: 
Minor allele frequency; NS: Not significant.
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differences, however, there was even no trend for a dif-
ference between UC and controls.
In addition, in an Italian study[27], the rs4958847 poly-
morphism was associated with fistulizing behavior (P = 
0.037, OR = 1.54, CI = 1.02-2.31) and perianal fistulas (P 
= 0.045, OR = 1.55, CI = 1.01-2.38) in a logistic regres-
sion analysis. This was later partially confirmed by the 
Leuven group. Henckaerts et al[28] have reported in a very 
elegant study a significant association between the IRGM 
rs4958847 variant, U7 gene desert rs12704036 T-allele, 
NOD2/CAR15 mutation, ileal involvement at diagnosis, 
male sex, and time to development of  non-perianal fistulas 
in a Cox regression analysis. In a further study from New 
Zealand[29], rs13361189 variant increased the risk for ileal 
CD in 507 CD patients and 576 controls. The OR in ileal 
CD was 1.92 (95% CI = 1.27-2.96). Moreover, Peterson 
et al[30] have suggested an association between IRGM and 
pediatric disease onset (< 17 years) of  CD in a North 
American cohort. However, only one of  the two IRGM 
variants studied (rs13361189) was weakly associated with 
CD in their study (uncorrected P = 0.03). In the present 
study, we could not confirm the association between age at 
onset and the presence of  the IRGM variant, in accordance 
with Canadian, Italian and Scottish results[29,31]. In contrast, 
we found an association between IRGM carriage and dis-
ease location in CD; colonic location was significantly more 
common in carriers of  the variant allele (OR = 1.62, 95% 
CI = 1.07-2.44). Of  note, however, the rs4958847 variant 
was not investigated in the present study.
The association between the rs10883365 variant of  
NKX2-3 gene and susceptibility of  IBD was first report-
ed in CD in Caucasian patients and in a Japanese study 
with an OR of  1.2-1.6[12-14]. In addition, using the UC pan-
el and the expanded WTCCC control panel, Fisher et al[15] 
have reported a modest association (P = 3.3 × 10-4 and P 
= 2.4 × 10-6) between rs10883365 and UC. In the present 
study, we confirmed these findings; the rs10883365 vari-
ant was associated with UC and CD susceptibility in the 
allelic and genotypic models with an OR of  1.53 and 1.24, 
respectively. Based on our data, the association between 
NKX2-3 and IBD is stronger in UC compared to CD, at 
least in patients from Eastern Europe. In a recent Dutch 
study, the association between the rs10883365 variant of  
NKX2-3 and CD was linked to smoking status, with the 
risk being more pronounced in active and passive smok-
ers[32]. In the present study, however, we did not find an 
association between NKX2-3 and smoking status, and 
similarly, no genotype-phenotype associations were found. 
In addition, Weersma et al[13] have created genetic risk 
profiles by combining the presence of  variant alleles in 
IL23R, ATG16L1, IRGM, NKX2-3, 1q24, 5p13, HERC2, 
CCNY, 10q21 and NOD2/CARD15, and the number of  
risk alleles was associated with gradually increased risk for 
CD. Similarly, in the present study, the combination of  
IRGM carrier/NKX2-3 homozygote genotype was asso-
ciated with an increased risk for CD, with a much higher 
OR compared to either of  the variant alleles alone.
Recently, an association between ECM1 rs3737240 and 
rs13294 variants and UC has been reported in a GWAS 
by Fisher et al[15], with an OR of  1.3-1.4 for the homozy-
gous carriage of  the variant allele. The association for the 
rs13294 variant has recently been confirmed in a Dutch 
study, with an OR of  1.24 in patients with UC[33]. In con-
trast, no association was found in CD[34], even though a 
different SNP (rs11205387) was investigated. Although 
the present study was powered to confirm a difference 
with an OR of  1.3-1.5 with adequate statistical power, 
we could not confirm an association between the ECM1 
rs13294 variant and either UC or CD. The accidental asso-
ciation between homozygous carriage of  the ECM1 vari-
ant allele and cutaneous manifestations (P = 0.002, OR 
= 3.36, 95% CI = 1.48-7.63, Figure 1B) requires further 
confirmation.
Theoretically, through influencing inflammatory re-
sponses, autophagy and epithelial-stromal interactions, 
polymorphisms in the above genes might be of  potential 
importance in altering the efficacy of  anti-inflammatory 
therapy and thereby the need for surgery. However, in the 
present study, none of  the variant alleles was associated 
with the response to either steroid or infliximab therapy, 
or the need for surgery (resection in CD or colectomy in 
UC) in IBD.
In conclusion, NKX2-3 and IRGM are susceptibility 
loci for IBD in Eastern European patients. None of  the 
variants investigated were associated with the need for 
surgery or efficacy of  medical therapy. Further studies 
are needed to confirm the reported phenotype-genotype 
associations found in this study. 
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wide association scans in North America and Western Europe.
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CD cohorts with strict clinical follow-up, that NKX2-3 rs10883365 variant allele 
was associated with increased susceptibility to CD and UC, whereas variant 
IRGM allele increased the risk for CD only. Our data suggest that the variant 
IRGM allele is associated with colon-only location, whereas in UC, the ECM1 
variant was associated with cutaneous manifestations. None of the variants 
predicted resistance to steroids and azathioprine, efficacy of infliximab, or need 
for surgery.
Application
The new data presented from Eastern Europe might contribute to better under-
standing of genetic or environmental differences between populations and the 
association of those differences with disease susceptibility and phenotype. 
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CD. The classification assesses the age at presentation, disease location and 
disease behavior. The IRGM gene encodes an autophagy-inducing protein and 
plays an important role in host defense against intracellular pathogens. NKX2-3 
is a member of the NKX family of homeodomain-containing transcription fac-
tors, which are implicated in many aspects of cell type specification and main-
tenance of differentiated tissue functions. ECM1 encodes extracellular matrix 
protein 1, a glycoprotein expressed in small and large intestine. Notably, ECM1 
strongly activates nuclear-κB signaling, a key immune regulator.
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Europe is valid, and provides a point for understanding subtle genetic or envi-
ronmental differences between populations and the association of those differ-
ences with disease.
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